UV1 cancer vaccine in pembrolizumab-treated patients with recurrent or metastatic PD-L1 positive head and neck squamous cell carcinoma: results from the randomized phase 2 FOCUS trial
Anna Brandt, Konrad Klinghammer, Christoph Schultheiss, Lisa Paschold, Claudia Wickenhauser, Marcus Bauer, Anna Bergqvist, Dennis Hahn, Philippe Schafhausen, Mareike Tometten, Markus Blaurock, Henrike Barbara Zech, Chia-Jung Busch, Andreas Dietz, Urs Müller-Richter, Jürgen Alt, Andreas Boehm, Simone Kowoll, Jörg Steighardt, Alexander Lasch, Ingunn Hagen Westgaard, Marita Westhrin, Alexander Stein, Axel Hinke, Mascha Binder
medRxiv 2024.10.24.24315748; doi: https://doi.org/10.1101/2024.10.24.24315748